The tweet was deleted by the author.
But we saved everything 🙂.
Eyepoint Pharmaceuticals announced its participation in the upcoming CTS Retina 2026 conference, set to take place in Las Vegas.
On June 13th, Dr. Ashkan M. Abbey and Dr. Tarek S. Hassan are scheduled to present the company’s most recent research and progress in treatments for retinal diseases. The event is expected to spotlight innovative approaches and emerging science in ophthalmology. Further details about the presentation and specific findings are anticipated as the conference date approaches.
Eyepoint has previously launched campaigns aimed at developing new treatments for severe retinal conditions such as DME, with activities highlighted during Mens Health Month in June. The company continues to focus research and innovation at its Northbridge facility to create therapies for patients affected by retinal diseases, as detailed in earlier reports on pipeline progress. The ongoing work sets the stage for the latest findings to be presented at the upcoming conference.